nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ABCB1—colon cancer	0.446	1	CbGaD
Mirabegron—BCHE—Irinotecan—colon cancer	0.13	0.278	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—colon cancer	0.0644	0.138	CbGbCtD
Mirabegron—ALB—Irinotecan—colon cancer	0.0629	0.135	CbGbCtD
Mirabegron—ALB—Fluorouracil—colon cancer	0.0603	0.129	CbGbCtD
Mirabegron—ALB—Methotrexate—colon cancer	0.0333	0.0713	CbGbCtD
Mirabegron—ABCB1—Irinotecan—colon cancer	0.0329	0.0705	CbGbCtD
Mirabegron—ABCB1—Vincristine—colon cancer	0.0287	0.0616	CbGbCtD
Mirabegron—CYP3A4—Irinotecan—colon cancer	0.0197	0.0422	CbGbCtD
Mirabegron—ABCB1—Methotrexate—colon cancer	0.0174	0.0373	CbGbCtD
Mirabegron—CYP3A4—Vincristine—colon cancer	0.0172	0.0369	CbGbCtD
Mirabegron—ORM1—bile—colon cancer	0.00828	0.313	CbGeAlD
Mirabegron—ORM1—gall bladder—colon cancer	0.0023	0.0868	CbGeAlD
Mirabegron—ALB—gall bladder—colon cancer	0.00202	0.0761	CbGeAlD
Mirabegron—Rash macular—Capecitabine—colon cancer	0.00175	0.0287	CcSEcCtD
Mirabegron—Joint swelling—Capecitabine—colon cancer	0.00146	0.024	CcSEcCtD
Mirabegron—Leukocytoclastic vasculitis—Methotrexate—colon cancer	0.00109	0.0178	CcSEcCtD
Mirabegron—SLCO1A2—renal system—colon cancer	0.000973	0.0367	CbGeAlD
Mirabegron—Neoplasm—Irinotecan—colon cancer	0.000968	0.0159	CcSEcCtD
Mirabegron—ORM1—bone marrow—colon cancer	0.000834	0.0315	CbGeAlD
Mirabegron—SLCO1A2—digestive system—colon cancer	0.000798	0.0301	CbGeAlD
Mirabegron—Cerebrovascular accident—Irinotecan—colon cancer	0.000793	0.013	CcSEcCtD
Mirabegron—Osteoarthritis—Irinotecan—colon cancer	0.000777	0.0128	CcSEcCtD
Mirabegron—Urinary retention—Vincristine—colon cancer	0.000759	0.0125	CcSEcCtD
Mirabegron—Osteoarthritis—Fluorouracil—colon cancer	0.000744	0.0122	CcSEcCtD
Mirabegron—ABCB1—blood vessel—colon cancer	0.000722	0.0273	CbGeAlD
Mirabegron—Aspartate aminotransferase increased—Vincristine—colon cancer	0.000718	0.0118	CcSEcCtD
Mirabegron—Blood pressure increased—Capecitabine—colon cancer	0.000716	0.0118	CcSEcCtD
Mirabegron—BCHE—smooth muscle tissue—colon cancer	0.000711	0.0268	CbGeAlD
Mirabegron—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.0007	0.0115	CcSEcCtD
Mirabegron—Abdominal distension—Irinotecan—colon cancer	0.000676	0.0111	CcSEcCtD
Mirabegron—ORM1—liver—colon cancer	0.000674	0.0255	CbGeAlD
Mirabegron—Nasopharyngitis—Fluorouracil—colon cancer	0.000665	0.0109	CcSEcCtD
Mirabegron—Dry eye—Capecitabine—colon cancer	0.000662	0.0109	CcSEcCtD
Mirabegron—Neoplasm—Capecitabine—colon cancer	0.000648	0.0106	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Irinotecan—colon cancer	0.000624	0.0102	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000598	0.00981	CcSEcCtD
Mirabegron—SLCO1A2—liver—colon cancer	0.000595	0.0225	CbGeAlD
Mirabegron—ALB—liver—colon cancer	0.000591	0.0223	CbGeAlD
Mirabegron—Vascular purpura—Capecitabine—colon cancer	0.000581	0.00954	CcSEcCtD
Mirabegron—Infestation NOS—Fluorouracil—colon cancer	0.000573	0.00941	CcSEcCtD
Mirabegron—Infestation—Fluorouracil—colon cancer	0.000573	0.00941	CcSEcCtD
Mirabegron—BCHE—digestive system—colon cancer	0.000561	0.0212	CbGeAlD
Mirabegron—Urinary tract infection—Fluorouracil—colon cancer	0.000557	0.00915	CcSEcCtD
Mirabegron—Atrial fibrillation—Capecitabine—colon cancer	0.000549	0.00901	CcSEcCtD
Mirabegron—Urinary tract disorder—Vincristine—colon cancer	0.000545	0.00895	CcSEcCtD
Mirabegron—Connective tissue disorder—Vincristine—colon cancer	0.000542	0.0089	CcSEcCtD
Mirabegron—Urethral disorder—Vincristine—colon cancer	0.000541	0.00888	CcSEcCtD
Mirabegron—Purpura—Capecitabine—colon cancer	0.00054	0.00886	CcSEcCtD
Mirabegron—Rhinitis—Irinotecan—colon cancer	0.000539	0.00884	CcSEcCtD
Mirabegron—Sinusitis—Fluorouracil—colon cancer	0.000538	0.00883	CcSEcCtD
Mirabegron—Cerebrovascular accident—Capecitabine—colon cancer	0.000531	0.00871	CcSEcCtD
Mirabegron—Connective tissue disorder—Irinotecan—colon cancer	0.000528	0.00867	CcSEcCtD
Mirabegron—Cystitis noninfective—Methotrexate—colon cancer	0.000521	0.00855	CcSEcCtD
Mirabegron—Osteoarthritis—Capecitabine—colon cancer	0.00052	0.00854	CcSEcCtD
Mirabegron—BCHE—bone marrow—colon cancer	0.000517	0.0195	CbGeAlD
Mirabegron—ORM1—lymph node—colon cancer	0.000517	0.0195	CbGeAlD
Mirabegron—Rhinitis—Fluorouracil—colon cancer	0.000516	0.00847	CcSEcCtD
Mirabegron—Cystitis—Methotrexate—colon cancer	0.000515	0.00845	CcSEcCtD
Mirabegron—Cardiac disorder—Vincristine—colon cancer	0.000512	0.00841	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—colon cancer	0.000503	0.00826	CcSEcCtD
Mirabegron—Cardiac disorder—Irinotecan—colon cancer	0.000499	0.00819	CcSEcCtD
Mirabegron—BCHE—vagina—colon cancer	0.000495	0.0187	CbGeAlD
Mirabegron—Urinary retention—Capecitabine—colon cancer	0.000494	0.00812	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—colon cancer	0.000482	0.00791	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—colon cancer	0.000482	0.00791	CcSEcCtD
Mirabegron—Breast disorder—Capecitabine—colon cancer	0.00047	0.00771	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000468	0.00769	CcSEcCtD
Mirabegron—Nasopharyngitis—Capecitabine—colon cancer	0.000465	0.00763	CcSEcCtD
Mirabegron—Back pain—Vincristine—colon cancer	0.000465	0.00763	CcSEcCtD
Mirabegron—CYP3A4—renal system—colon cancer	0.000461	0.0174	CbGeAlD
Mirabegron—Gastritis—Capecitabine—colon cancer	0.00046	0.00755	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000459	0.00753	CcSEcCtD
Mirabegron—ALB—lymph node—colon cancer	0.000453	0.0171	CbGeAlD
Mirabegron—CYP2D6—renal system—colon cancer	0.000453	0.0171	CbGeAlD
Mirabegron—Back pain—Irinotecan—colon cancer	0.000453	0.00743	CcSEcCtD
Mirabegron—Abdominal distension—Capecitabine—colon cancer	0.000452	0.00743	CcSEcCtD
Mirabegron—Influenza—Capecitabine—colon cancer	0.000449	0.00738	CcSEcCtD
Mirabegron—ABCB1—embryo—colon cancer	0.000431	0.0163	CbGeAlD
Mirabegron—Vision blurred—Fluorouracil—colon cancer	0.000422	0.00693	CcSEcCtD
Mirabegron—BCHE—liver—colon cancer	0.000418	0.0158	CbGeAlD
Mirabegron—Upper respiratory tract infection—Capecitabine—colon cancer	0.000418	0.00686	CcSEcCtD
Mirabegron—Hypertension—Vincristine—colon cancer	0.000415	0.00681	CcSEcCtD
Mirabegron—Hypertension—Irinotecan—colon cancer	0.000404	0.00663	CcSEcCtD
Mirabegron—Infestation NOS—Capecitabine—colon cancer	0.000401	0.00658	CcSEcCtD
Mirabegron—Infestation—Capecitabine—colon cancer	0.000401	0.00658	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000397	0.00652	CcSEcCtD
Mirabegron—Cerebrovascular accident—Methotrexate—colon cancer	0.000395	0.00648	CcSEcCtD
Mirabegron—Infection—Vincristine—colon cancer	0.00039	0.00639	CcSEcCtD
Mirabegron—Urinary tract infection—Capecitabine—colon cancer	0.00039	0.00639	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—colon cancer	0.000387	0.00635	CcSEcCtD
Mirabegron—Infection—Irinotecan—colon cancer	0.000379	0.00623	CcSEcCtD
Mirabegron—CYP3A4—digestive system—colon cancer	0.000378	0.0143	CbGeAlD
Mirabegron—CYP2D6—digestive system—colon cancer	0.000372	0.014	CbGeAlD
Mirabegron—Infection—Fluorouracil—colon cancer	0.000363	0.00596	CcSEcCtD
Mirabegron—Rhinitis—Capecitabine—colon cancer	0.000361	0.00592	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vincristine—colon cancer	0.000357	0.00586	CcSEcCtD
Mirabegron—Tachycardia—Fluorouracil—colon cancer	0.000357	0.00586	CcSEcCtD
Mirabegron—Urinary tract disorder—Capecitabine—colon cancer	0.000355	0.00583	CcSEcCtD
Mirabegron—Connective tissue disorder—Capecitabine—colon cancer	0.000354	0.0058	CcSEcCtD
Mirabegron—Urethral disorder—Capecitabine—colon cancer	0.000353	0.00579	CcSEcCtD
Mirabegron—ABCB1—epithelium—colon cancer	0.000351	0.0133	CbGeAlD
Mirabegron—Breast disorder—Methotrexate—colon cancer	0.00035	0.00574	CcSEcCtD
Mirabegron—Erythema multiforme—Capecitabine—colon cancer	0.00034	0.00558	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vincristine—colon cancer	0.000339	0.00556	CcSEcCtD
Mirabegron—Fatigue—Vincristine—colon cancer	0.000338	0.00555	CcSEcCtD
Mirabegron—Eye disorder—Capecitabine—colon cancer	0.000336	0.00552	CcSEcCtD
Mirabegron—Dyspepsia—Irinotecan—colon cancer	0.000336	0.00552	CcSEcCtD
Mirabegron—Constipation—Vincristine—colon cancer	0.000335	0.0055	CcSEcCtD
Mirabegron—Cardiac disorder—Capecitabine—colon cancer	0.000334	0.00548	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000333	0.00547	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Irinotecan—colon cancer	0.00033	0.00541	CcSEcCtD
Mirabegron—Fatigue—Irinotecan—colon cancer	0.000329	0.0054	CcSEcCtD
Mirabegron—Constipation—Irinotecan—colon cancer	0.000327	0.00536	CcSEcCtD
Mirabegron—ABCB1—renal system—colon cancer	0.000326	0.0123	CbGeAlD
Mirabegron—Dyspepsia—Fluorouracil—colon cancer	0.000322	0.00528	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vincristine—colon cancer	0.000321	0.00526	CcSEcCtD
Mirabegron—BCHE—lymph node—colon cancer	0.00032	0.0121	CbGeAlD
Mirabegron—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000316	0.00518	CcSEcCtD
Mirabegron—Gastrointestinal pain—Irinotecan—colon cancer	0.000312	0.00513	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—colon cancer	0.000311	0.0051	CcSEcCtD
Mirabegron—Abdominal pain—Vincristine—colon cancer	0.00031	0.00509	CcSEcCtD
Mirabegron—Back pain—Capecitabine—colon cancer	0.000303	0.00497	CcSEcCtD
Mirabegron—Abdominal pain—Irinotecan—colon cancer	0.000302	0.00495	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—colon cancer	0.000298	0.0049	CcSEcCtD
Mirabegron—Infestation—Methotrexate—colon cancer	0.000298	0.0049	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000296	0.00485	CcSEcCtD
Mirabegron—Vision blurred—Capecitabine—colon cancer	0.000295	0.00484	CcSEcCtD
Mirabegron—Urticaria—Fluorouracil—colon cancer	0.000291	0.00477	CcSEcCtD
Mirabegron—CYP3A4—liver—colon cancer	0.000281	0.0106	CbGeAlD
Mirabegron—Asthenia—Vincristine—colon cancer	0.000281	0.00462	CcSEcCtD
Mirabegron—CYP2D6—liver—colon cancer	0.000277	0.0105	CbGeAlD
Mirabegron—Palpitations—Capecitabine—colon cancer	0.000277	0.00454	CcSEcCtD
Mirabegron—Asthenia—Irinotecan—colon cancer	0.000274	0.0045	CcSEcCtD
Mirabegron—ABCB1—lymphoid tissue—colon cancer	0.000271	0.0102	CbGeAlD
Mirabegron—Hypertension—Capecitabine—colon cancer	0.00027	0.00444	CcSEcCtD
Mirabegron—Diarrhoea—Vincristine—colon cancer	0.000268	0.0044	CcSEcCtD
Mirabegron—ABCB1—digestive system—colon cancer	0.000267	0.0101	CbGeAlD
Mirabegron—Arthralgia—Capecitabine—colon cancer	0.000267	0.00438	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000265	0.00435	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—colon cancer	0.000264	0.00434	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—colon cancer	0.000263	0.00431	CcSEcCtD
Mirabegron—Diarrhoea—Irinotecan—colon cancer	0.000261	0.00429	CcSEcCtD
Mirabegron—Dry mouth—Capecitabine—colon cancer	0.000261	0.00428	CcSEcCtD
Mirabegron—Dizziness—Vincristine—colon cancer	0.000259	0.00426	CcSEcCtD
Mirabegron—Pruritus—Fluorouracil—colon cancer	0.000259	0.00425	CcSEcCtD
Mirabegron—Infection—Capecitabine—colon cancer	0.000254	0.00417	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—colon cancer	0.000253	0.00416	CcSEcCtD
Mirabegron—Dizziness—Irinotecan—colon cancer	0.000253	0.00414	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—colon cancer	0.00025	0.00411	CcSEcCtD
Mirabegron—Diarrhoea—Fluorouracil—colon cancer	0.00025	0.00411	CcSEcCtD
Mirabegron—Tachycardia—Capecitabine—colon cancer	0.000249	0.00409	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—colon cancer	0.000249	0.00408	CcSEcCtD
Mirabegron—Skin disorder—Capecitabine—colon cancer	0.000248	0.00407	CcSEcCtD
Mirabegron—Rash—Vincristine—colon cancer	0.000247	0.00406	CcSEcCtD
Mirabegron—Dermatitis—Vincristine—colon cancer	0.000247	0.00405	CcSEcCtD
Mirabegron—ABCB1—bone marrow—colon cancer	0.000246	0.00931	CbGeAlD
Mirabegron—Headache—Vincristine—colon cancer	0.000246	0.00403	CcSEcCtD
Mirabegron—Dizziness—Fluorouracil—colon cancer	0.000242	0.00397	CcSEcCtD
Mirabegron—Rash—Irinotecan—colon cancer	0.000241	0.00395	CcSEcCtD
Mirabegron—Dermatitis—Irinotecan—colon cancer	0.000241	0.00395	CcSEcCtD
Mirabegron—Headache—Irinotecan—colon cancer	0.000239	0.00393	CcSEcCtD
Mirabegron—ABCB1—vagina—colon cancer	0.000236	0.00891	CbGeAlD
Mirabegron—Nausea—Vincristine—colon cancer	0.000233	0.00382	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000233	0.00382	CcSEcCtD
Mirabegron—Rash—Fluorouracil—colon cancer	0.000231	0.00379	CcSEcCtD
Mirabegron—Dermatitis—Fluorouracil—colon cancer	0.00023	0.00378	CcSEcCtD
Mirabegron—Headache—Fluorouracil—colon cancer	0.000229	0.00376	CcSEcCtD
Mirabegron—Nausea—Irinotecan—colon cancer	0.000227	0.00372	CcSEcCtD
Mirabegron—Back pain—Methotrexate—colon cancer	0.000226	0.0037	CcSEcCtD
Mirabegron—Dyspepsia—Capecitabine—colon cancer	0.000225	0.00369	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Capecitabine—colon cancer	0.000221	0.00362	CcSEcCtD
Mirabegron—Fatigue—Capecitabine—colon cancer	0.00022	0.00362	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—colon cancer	0.00022	0.00361	CcSEcCtD
Mirabegron—Constipation—Capecitabine—colon cancer	0.000219	0.00359	CcSEcCtD
Mirabegron—Nausea—Fluorouracil—colon cancer	0.000217	0.00357	CcSEcCtD
Mirabegron—Gastrointestinal pain—Capecitabine—colon cancer	0.000209	0.00343	CcSEcCtD
Mirabegron—Urticaria—Capecitabine—colon cancer	0.000203	0.00333	CcSEcCtD
Mirabegron—Abdominal pain—Capecitabine—colon cancer	0.000202	0.00332	CcSEcCtD
Mirabegron—ABCB1—liver—colon cancer	0.000199	0.00752	CbGeAlD
Mirabegron—Arthralgia—Methotrexate—colon cancer	0.000198	0.00326	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000197	0.00324	CcSEcCtD
Mirabegron—Infection—Methotrexate—colon cancer	0.000189	0.0031	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—colon cancer	0.000185	0.00303	CcSEcCtD
Mirabegron—Asthenia—Capecitabine—colon cancer	0.000183	0.00301	CcSEcCtD
Mirabegron—Pruritus—Capecitabine—colon cancer	0.000181	0.00297	CcSEcCtD
Mirabegron—Diarrhoea—Capecitabine—colon cancer	0.000175	0.00287	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000173	0.00285	CcSEcCtD
Mirabegron—Dizziness—Capecitabine—colon cancer	0.000169	0.00277	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—colon cancer	0.000167	0.00275	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—colon cancer	0.000164	0.0027	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—colon cancer	0.000164	0.00269	CcSEcCtD
Mirabegron—Rash—Capecitabine—colon cancer	0.000161	0.00264	CcSEcCtD
Mirabegron—Dermatitis—Capecitabine—colon cancer	0.000161	0.00264	CcSEcCtD
Mirabegron—Headache—Capecitabine—colon cancer	0.00016	0.00263	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—colon cancer	0.000156	0.00255	CcSEcCtD
Mirabegron—ABCB1—lymph node—colon cancer	0.000153	0.00577	CbGeAlD
Mirabegron—Nausea—Capecitabine—colon cancer	0.000152	0.00249	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—colon cancer	0.000151	0.00248	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—colon cancer	0.00015	0.00247	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—colon cancer	0.000137	0.00224	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—colon cancer	0.000135	0.00221	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—colon cancer	0.00013	0.00214	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—colon cancer	0.000126	0.00207	CcSEcCtD
Mirabegron—Rash—Methotrexate—colon cancer	0.00012	0.00197	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—colon cancer	0.00012	0.00197	CcSEcCtD
Mirabegron—Headache—Methotrexate—colon cancer	0.000119	0.00196	CcSEcCtD
Mirabegron—Nausea—Methotrexate—colon cancer	0.000113	0.00185	CcSEcCtD
